Literature DB >> 9220170

Production of polyclonal antibodies to feline tumor necrosis factor.

C M Otto1, F Niagro, R A McGraw, C A Rawlings.   

Abstract

Two 13-amino-acid peptides were synthesized based on the putative feline tumor necrosis factor (FeTNF) sequence. The synthesized peptides were conjugated to keyhole limpet hemocyanin, emulsified in complete Freund's adjuvant, and injected into rabbits. The gene for FeTNF was cloned into the FLAG (International Biotechnologies Inc. [IBI], Kodak, New Haven, Conn.) fusion protein expression vector. The expressed fusion protein was purified by using the M-1 anti-FLAG octapeptide monoclonal antibody (IBI, Kodak). The fusion protein was emulsified in complete Freund's adjuvant and injected into chickens. The immune sera generated to the synthetic peptides and the fusion protein recognized the recombinant FeTNF fusion protein on Western or dot blot assay. The preimmune and immune sera were incubated with naturally occurring FeTNF (supernatants from lipopolysaccharide-stimulated cultured feline peritoneal exudate or peripheral mononuclear cells). The antibody raised to the recombinant FeTNF fusion protein and N-terminal synthetic peptide neutralized bioactivity of native FeTNF and recombinant human TNF. Preimmune sera did not have any neutralizing activity. The polyclonal antibodies were not specific for FeTNF, since both porcine and human recombinant TNF were neutralized by the fusion protein antibodies. The synthetic peptide antibodies recognized recombinant feline and equine TNF on a Western blot.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220170      PMCID: PMC170556          DOI: 10.1128/cdli.4.4.487-490.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  30 in total

1.  Gene sequence of feline tumor necrosis factor alpha.

Authors:  R A McGraw; B W Coffee; C M Otto; R T Drews; C A Rawlings
Journal:  Nucleic Acids Res       Date:  1990-09-25       Impact factor: 16.971

Review 2.  Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin.

Authors:  M Jäättelä
Journal:  Lab Invest       Date:  1991-06       Impact factor: 5.662

Review 3.  Inflammatory cytokines.

Authors:  A Cerami
Journal:  Clin Immunol Immunopathol       Date:  1992-01

Review 4.  Synthetic peptide vaccines against pathogens and biological mediators.

Authors:  G J Riveau; F M Audibert
Journal:  Trends Pharmacol Sci       Date:  1990-05       Impact factor: 14.819

5.  Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes.

Authors:  T S Bringman; B B Aggarwal
Journal:  Hybridoma       Date:  1987-10

6.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.

Authors:  R M Horton; H D Hunt; S N Ho; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

7.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

8.  Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models.

Authors:  B A Sherry; J Gelin; Y Fong; M Marano; H Wei; A Cerami; S F Lowry; K G Lundholm; L L Moldawer
Journal:  FASEB J       Date:  1989-06       Impact factor: 5.191

9.  Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice.

Authors:  N Takahashi; P Brouckaert; W Fiers
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

10.  Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.

Authors:  A T Silva; K F Bayston; J Cohen
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

View more
  1 in total

1.  Inhibitory effect of antiserum to surface antigen P50 of Babesia gibsoni on growth of parasites in severe combined immunodeficiency mice given canine red blood cells.

Authors:  Shinya Fukumoto; Xuenan Xuan; Noriyuki Takabatake; Ikuo Igarashi; Chihiro Sugimoto; Kozo Fujisaki; Hideyuki Nagasawa; Takeshi Mikami; Hiroshi Suzuki
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.